Phase 1 N=82 A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change From Baseline (Day -1) in Mean Daily Glucose at Day 14 — 228.67; 233.20; 219.13; 229.92 milligram/deciliter (mg/dL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=578 Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
HIV Infections
Primary: Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale…
N/A N=17 Pediatric Aggression and Violence
Pediatric Aggression and Violence
Primary: Salivary Hormone Correlation With Brief Rating of Aggression by Children and Adolescent (BRACHA) Score — 0.8; 0.4; 0.3; 0.4 ul/dL
Phase 3 N=240 RNS® System Pivotal Study
Epilepsy
Primary: Acute SAE Rate — 12.0 percentage of subjects with ≥ 1 SAE
Phase 4 N=268 A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
Infection · Cross Infection · Bacterial Infections
Primary: Number of Participants With Adverse Events (AEs) and Number of Participants Discontinued Because of AEs — 66; 22; 56; 0 Participants
N/A N=327 Method Comparison Study of the Spartan FRX CYP2C19 Genotyping System Against Bi-directional Sequencing
Genotyping Techniques
Primary: Percent Agreement — 100; 100; 100; 100 Percent Agreement
Phase 2 N=208 The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women
Bone Resorption · Osteoporosis
Primary: Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline — 0.51; 0.51 percentage change
N/A N=12 The Differential Effects of 3 Different Immunosuppressive
Immunosuppression · Kidney Transplantation
Primary: CD4+CD25 High FOXP3+ Cell Levels in Mixed Lymphocyte Reactions (MLRs) of Renal Pre-transplant Recipients/Donors — 90; 85; 25; 50 Percentage of Control Cells
Phase 3 N=6,635 Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Respiratory Syncytial Virus Infections
Primary: Incidence of RSV Hospitalization (Includes Deaths by RSV) — 62; 46 Participants
N/A N=100 Impact of Adherence to Treatment in Asthma Control
Asthma
Primary: Analyze How Adherence to Treatment Using ASK-20 Questionnaire Influences Level of Asthma Control. — 34; 32 units on a scale — p=0.967
N/A N=30 Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women
Pregnancy
Primary: Comparison of SureCALL® and Tocodynamometer Detection of Contraction Event Timing — 0.99 Seconds — p=0.4901
N/A N=30 Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients
Swallowing Disorder · Aspiration · Long Term Ventilation
Primary: Muscle Strength — 20; 10 participants
Phase 4 N=20 A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
HIV Infections
Primary: Immune Reconstitution [3 Months] — 41.56; 49.40 cells per cubic millimeter — p=0.81
N/A N=30 Ultherapy™ Treatment Following Sculptra® Treatment
Skin Laxity
Primary: Lifting and Tightening of Skin as Determined by Masked Assessment of Pre- and Post-treatment Photographs. — 40; 30; 33 percentage of participants improved
Phase 4 N=140 Efficacy and Safety Profiles of Combination Sedation Propofol With Midazolam and Meperidine.
Disorders of Gallbladder, Biliary Tract and Pancrease
Primary: Procedure Related Time — 40.67; 43.24; 3.94; 5.47 minutes — p=0.05